These data suggest that a combination of avasimibe and imatinib could be a promising therapeutic strategy to treat imatinib-resistant CML without BCR-ABL kinase domain mutations. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.